Insys Therapeutics Inc (NASDAQ:INSY) has issued an update on the naloxone nasal and epinephrine sprays and CBD oral solutions. CEO and President of Insys Therapeutics, Saeed Motahari said the company is focusing on novel drug delivery systems and pharmaceutical grade cannabinoids to drive the growth going forward. It is moving away from opioids. The company is transforming its business strategy to include patient-centric formulations over the past one year. Going forward, Insys Therapeutics is preparing to submit 6 innovative drug applications in the next 3 years. The company is scheduling two of them in 2019.
An update on the Opioid Related Assets
As per the announced plans, Insys Therapeutics is scheduling the alternative review of the opioid related assets. As of now, nine firms have entered into a pact with Insys Therapeutics and are reviewing the confidential information. The company will release an update on this aspect in early 2019.
An Update on the Lifesaving Products
Insys Therapeutics is in the advanced stages of developing the lifesaving investigational products that are based on spray technologies. Its lifesaving products in development include epinephrine nasal spray for anaphylaxis and naloxone nasal spray for the opioid overdose.
The next big cannabis story to hit North America is Phoenix Life Science International (PLSI), traded in the US, but with the largest global production based in the tropics and a license to distribute worldwide. Take a look at Phoenix Life Science International PLSI), Its currently trading under $18 dollars per share on the OTC markets. Learn More Now!
The company is also focusing on cannabinoids like CBD oral solution targeting the child absence epilepsy treatment (phase 2), Prader Willi Syndrome (phase 2), infantile spasms (phase 3), and dronabinol inhalation to treat a variety of conditions such as anorexia in patients suffering from cancer.
Insys Therapeutics is conducting a non-clinical toxicity study on naloxone nasal spray and expects to announce the results in March 2019. The company has set the timeframe for the NDA submission in Q1 2019.
Epinephrine nasal spray, which is intended for needle-free delivery, is a substitute to the intramuscular injection. According to the study, it is readily absorbed via the nasal mucosa. The company has obtained FDA nod for fast track designation for the drug in August 2018. It has also provided specific guidelines for filing requirement and clinical development. Insys Therapeutics is optimistic to complete the filing requirements for epinephrine NDA in Q4, 2019. It is subject to successful completion of PK study.
The company has successfully completed a proof of concept study on dronabinol inhalation in September 2018. Insys Therapeutics will arrange a meeting with clinical experts in Q1 2019 to discuss further development for this investigational formulation.
Insys Therapeutics Signs a Pact with Lunatus for Commercializing SUBSYS
Insys Therapeutics has signed a definitive accord with Lunatus for commercializing Subsys in 8 nations in the Middle East. Following the deal, Lunatus will act as an authorized agent and licensee in the UAE, Lebanon, Kuwait, Jordan, Saudi Arabia, Qatar, Oman, and Bahrain.
Pushing the barriers for global distribution, Phoenix Life Science International (PLSI) is the next cannabis play. Just think Canopy x 100, that is how big their plantation in the tropics will be. No lights, no green houses, just maximum growth + minimal cost = home run. Learn More Now!
Auxly Cannabis Group Inc (OTCMKTS:CBWTF) Acquires 46% Stake In Curative Cannabis And Agrees to Fund Cannabis Cultivation Facility To Produce Ultra Premium Cannabis
Auxly Cannabis Group Inc (OTCMKTS:CBWTF) has entered a deal to take over a 46% stake in Curative Cannabis. The company...
Canntrust Holdings Inc. (OTCMKTS:CNTTF) Receive Permission From The Town Of Pelham For Their Third Phase Construction
CannTrust Holdings Inc. (OTCMKTS:CNTTF) has announced that they have obtained the required permit to go on with the third phase...
Indiva Ltd (OTCMKTS:NDVAF) Announces 9.9% Equity Investment In Retailgo Inc.
Indiva Ltd (OTCMKTS:NDVAF) has announced that they are delighted to have finalized an Equity investment of 9.9% in RetailGo Inc....
Future Farm Technologies Inc (OTCMKTS:FFRMF) Plans To Begin Selling Of Cheery Wine Strain Hemp Seeds And Test Operation Of The Oil Extraction Equipment
Future Farm Technologies Inc (OTCMKTS:FFRMF) is planning to commence the selling of the elite cherry Wine hemp seeds by putting...
OrganiGram Holdings Inc (OTCMKTS:OGRMF) Sources Hemp With High Levels of CBD From 1812 Hemp
OrganiGram Holdings Inc (OTCMKTS:OGRMF) has entered into a supply pact with 1812 Hemp, an industrial hemp research company based in...
Kona Gold Solutions Inc (OTCMKTS:KGKG) Declares That They Have Acquired Gold Leaf Distribution
Kona Gold Solutions Inc (OTCMKTS:KGKG) has announced the acquisition of Gold Leaf distribution a newly established distribution company. The Florida...
CFN Media Group features Supreme Cannabis Company (OTCMKTS:SPRWF) as consideration for investors as their 2019 stock scales up
CFNB Media Group has announced a publication on Supreme Cannabis Company (OTCMKTS:SPRWF) as a licensed producer obsessed with quality. Supreme...
Village Farms International Inc (OTCMKTS:VFFIF) Leading Greenhouse Crop Protection And Announces Plans To List Its Common Shares On The NASDAQ Market
Village Farms International Inc (OTCMKTS:VFFIF) has announced that they have facilitated Health Canada Pest Management Agency to get approval for...
Sunniva Inc. (OTCMKTS:SNNVF) Secures More Funding For Growth Strategy As Plans Solidify Towards A Tremendous Year
Sunniva Inc. (OTCMKTS:SNNVF) is solidifying its growth strategy in anticipation for exponential growth this year. Notably, the firm acquired a...
Curis, Inc. (NASDAQ:CRIS) Announce The Dosing Of The First Mesothelioma Patient In The First Phase Of The CA-170 Study
Curis, Inc. (NASDAQ:CRIS) has announced the enrolment and dosing of the first mesothelioma patient in the first phase of the...